UniCredit Bank GmbH Share Price

Certificat

DE000HC6UT60

Real-time BOERSE MUENCHEN 03:15:17 01/07/2024 pm IST
52.02 EUR +0.89% Intraday chart for UniCredit Bank GmbH
Current month+1.14%
1 month-3.41%
Date Price Change
01/24/01 52.02 +0.89%
28/24/28 51.56 +4.75%
27/24/27 49.22 -3.64%
26/24/26 51.08 +0.24%
25/24/25 50.96 +3.07%

Real-time BOERSE MUENCHEN

Last update July 01, 2024 at 03:15 pm IST

More quotes

Static data

Product typeAktienanleihen
Buy / SellCALL
Underlying EVOTEC SE
IssuerLogo Issuer UniCredit UniCredit
WKN HC6UT6
ISINDE000HC6UT60
Date issued 19/05/2023
Strike 18
Maturity 16/08/2024 (47 Days)
Parity 0.02 : 1
Emission price 100.7
Emission volume N/A
Settlement Beides
Currency EUR

Technical Indicators

Highest since issue 107.2
Lowest since issue 43.17
Spread 1.3
Spread %0.25%

Company Profile

Evotec SE is a Germany-based drug discovery and development company. The company is engaged in development of new pharmaceutical products through research alliances and development partnerships with pharmaceutical and biotechnology companies, academic institutions, patient organizations and venture capital companies. The drug discovery solutions are provided in the form of fee-for-service work, integrated drug discovery alliances, development partnerships, licensing of drug candidates and consulting arrangements. Evotec SE operates in a number of areas, including neuroscience, diabetes and complications of diabetes, pain and inflammation, oncology, infectious diseases, respiratory diseases and fibrosis. Its pipeline covers a range of therapeutic areas, such as CNS Insomnia, Chronic cough, immunology & inflammation, women’s health endometriosis, nephrology, dermatological diseases, fibrotic disease and antiviral, among others.
Sector
-
More about the company

Ratings for Evotec SE

Trading Rating
Investor Rating
ESG Refinitiv
A-
More Ratings

Consensus: Evotec SE

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
10
Last Close Price
8.975 EUR
Average target price
20.79 EUR
Spread / Average Target
+131.64%
Consensus